Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $64
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $58 to $64.
Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $58 to $64.